GMTX Insider Trading Activity and SEC Form 4 Filings
GMTX insider trading summary
No open-market insider purchases or sales of Gemini Therapeutics, Inc. (GMTX) have been reported on SEC Form 4 in the past 12 months.
Latest GMTX insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Oct 26, 2022 | Braden Michael Leonard | 10% Owner | Sell | $47K (22,500 @ $2.09) |
| Apr 13, 2022 | Braden Michael Leonard | 10% Owner | Buy | $292K (191,769 @ $1.52) |
| Apr 12, 2022 | Braden Michael Leonard | 10% Owner | Buy | $75K (55,000 @ $1.36) |
| Apr 12, 2022 | Braden Michael Leonard | 10% Owner | Buy | $290K (203,744 @ $1.42) |
| Apr 11, 2022 | Braden Michael Leonard | 10% Owner | Buy | $681K (504,487 @ $1.35) |
| May 14, 2021 | Brian Piekos | Chief Financial Officer | Buy | $72K (7,655 @ $9.46) |
| May 14, 2021 | Jason Patrick Meyenburg | President & CEO | Buy | $123K (13,000 @ $9.46) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.